IQVIA MedTech’s Post

How are GLP-1s impacting your business? If you’re not clear, it’s time to cut through the noise with IQVIA MedTech, as our experts uncover the challenges and opportunities of GLP-1s – allowing you to plan with confidence for a successful MedTech future. Watch on-demand: https://bit.ly/3RNmwNf #GLP1 #MedTech

How are GLP-1s impacting your business? If you’re not clear, it’s time to cut through the noise with IQVIA MedTech, as our experts uncover the challenges and opportunities of GLP-1s – allowing you to plan with confidence for a successful MedTech future. Watch on-demand: https://bit.ly/3zPPplX #GLP1 #MedTech

How are GLP-1s impacting your business? If you’re not clear, it’s time to cut through the noise with IQVIA MedTech, as our experts uncover the challenges and opportunities of GLP-1s – allowing you to plan with confidence for a successful MedTech future. Watch on-demand: https://lnkd.in/eiKuWdsJ #GLP1 Joanna Wills

Do you have the real picture on how GLP-1s are impacting your business? Join IQVIA MedTech on March 7 to learn how to plan with confidence for a successful MedTech future.

🏛️ Welcome to Consultants Corner, where we check in with independent experts about questions they are answering or challenges they are solving for clients on the front lines of medtech regulatory, reimbursement, and market access. 💡 In this edition of Consultants Corner, insights on US, EU, and UK regulatory strategies from Michelle Lott, RAC, Gert Bos, PhD, FRAPS, and Matt Burton, who each spoke at the 2024 MedTech Regulatory Global Pathways Virtual Summit earlier this month: https://bit.ly/3V1HdaG #medtech #medicaldevices #regulatory #regulatoryaffairs #reimbursement #marketaccess #medtechindustry

Iain's Industry Insights covering the latest Investments, Innovation and MedTech Insights. Some exciting investment stories that could unlock the potential of some fantastic innovation; a couple of FDA approvals for two MedTech goliaths and a couple of significant C-Suite changes. Links to all articles in the comments. Keep on making a difference! #medtech #insidemedtech #medicaltechnology #medicaldevices #industrynews

With GLP-1s being used by more and more consumers, many see them as the closest thing #medicine has to a silver bullet for a host of costly diseases. With still so much uncertainty around the magnitude and breadth of the impact on existing medical drugs, devices, and procedures, leaders in the #healthcare and #lifesciences industries need to adapt their business strategies to win big in this new era for healthcare. Learn how: https://bit.ly/4a3ixCZ Authors: Betty Pio, Cian Wade, and Fernando Perez-Hickman Escolar

Unlock the potential of GLP-1 treatments through insights extracted from unstructured conversational data. Our blog explores how these insights are shaping understanding of patient and healthcare professional perspectives. Learn more about the revolutionary impact of GLP-1 drugs in modern healthcare by clicking the link below. https://hubs.la/Q02JHTgz0

With GLP-1s being used by more and more consumers, many see them as the closest thing #medicine has to a silver bullet for a host of costly diseases. With still so much uncertainty around the magnitude and breadth of the impact on existing medical drugs, devices, and procedures, leaders in the #healthcare and #lifesciences industries need to adapt their business strategies to win big in this new era for healthcare. Learn how: Authors: Betty Pio, Cian Wade ,and Fernando Perez-Hickman Escolar

🔍 Million dollar question: where should you launch a new medical device or combination product first, in the EU or in the US? What are the current challenges in both areas? 🤔 If you wondered abou that, come meet us at the Swiss National Regulatory Conference, and let's discuss the best approach together. confinis will be engaging with peers and industry experts on the key regulatory challenges facing Europe today as part of Swiss Medtech. 🌍🩺 We’re excited to share insights and help you navigate these complex times. #innovators #regulatory #compliance #andbeyond #SwissRegulatoryConference #MedTech #RegulatoryStrategy #EUvsFDA